<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene S494P literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.S494P</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using molecular dynamic simulation, the mildly (~1kcal/mol) enhanced binding energy of this variant is primarily  contributed by Tyr505 (âˆ’4.98 kcal/mol) which is now involved in a strong hydrogen bonding network with Arg393.<br/>Another important energetic contribution comes from the altered orientation of Tyr41 which is now involved with  two hydrogen-bonding interactions with Asp355 and Thr500. <br/> (<a href="https://doi.org/10.1016/j.bbrc.2021.01.035" class="lit_link">Chakraborty (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Minor variant selected in late rounds of an in vitro evolution experiment for ACE2 binding.<br/>Shown to increase the thermostability but decrease the association rate constant of the RBD to ACE2 (<a href="https://doi.org/10.1101/2021.01.06.425392" class="lit_link">Zahradnik et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Highly resistant to mAb SARS2-01 of 10 antibodies tested.<br/> (<a href="https://doi.org/10.1016/j.chom.2021.01.014" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2020)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.<br/> (<a href="https://doi.org/10.1126/science.abf4830" class="lit_link">Rappazzo et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,  S484P shows a slightly resistant profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution) (<a href="https://doi.org/10.1016/j.chom.2021.02.003" class="lit_link">Greaney et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.<br/> (<a href="https://doi.org/10.1101/2020.11.06.372037" class="lit_link">Liu et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="monoclonal_antibody_serial_passage_escape">Monoclonal antibody serial passage escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab) (<a href="https://doi.org/10.1101/2021.02.17.431683" class="lit_link">Starr et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.<br/>Regdanvimab lost ~32x binding against this isolated mutation. (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
